Forside > Investment cases > Biosergen

Biosergen investeringscase

About Biosergen

Biosergen AB is a biopharmaceutical company that was listed on Nasdaq First North Sweden in June 2021. The company develops innovative antifungal drugs based on the latest biopharmaceutical research and development from laboratory facilities in Trondheim, Norway and several other locations around the world.

The company is developing BSG005, a potential antifungal drug that has demonstrated significant safety data and potency advantages over competing antifungal agents. BSG005, which is in clinical phase I (the first of three phases of development towards the market), could potentially reach the market as early as 2026/27

Forside > Investment cases > Biosergen

Del indlægget på sociale media eller på email.